Emergent Biosolutions - 4 Year Dividend History | EBS

Historical dividend payout and yield for Emergent Biosolutions (EBS) since 2018. The current TTM dividend payout for Emergent Biosolutions (EBS) as of September 26, 2022 is $0.00. The current dividend yield for Emergent Biosolutions as of September 26, 2022 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.040B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio